home / stock / ambs / ambs quote
Last: | $0.0001 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0001 |
Close: | $0.0001 |
High: | $0.0001 |
Low: | $0.0001 |
Volume: | 8,267 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 8,267 | 05-03-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 320 | 05-01-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 100,000 | 04-29-2024 |
$1e-06 | $1e-06 | $1e-06 | $0.0001 | $1e-06 | 1,219,564 | 04-23-2024 |
$1e-06 | $1e-06 | $1e-06 | $0.0001 | $1e-06 | 43,100 | 04-22-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 200,000 | 04-18-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 2,800 | 04-17-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 1,167 | 04-15-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 6,334 | 04-12-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 220,000 | 04-11-2024 |
$0.0001 | $0 | $0.0001 | $0 | $0 | 34 | 04-09-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 257,420 | 04-05-2024 |
$0.0001 | $0 | $0.0001 | $0 | $0 | 16 | 04-02-2024 |
$0.0001 | $0 | $0.0001 | $0 | $0 | 4 | 04-01-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 822 | 03-27-2024 |
$0.0001 | $0 | $0.0001 | $0 | $0 | 67 | 03-26-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 2,000 | 03-25-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 11,172 | 03-22-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 1,793,487 | 03-21-2024 |
$0.0001 | $0.0001 | $0.0001 | $0.0001 | $0.0001 | 111,452 | 03-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Amarantus BioScience Holdings Inc Company Name:
AMBS Stock Symbol:
OTCMKTS Market:
Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs NEW YORK, NY / ACCESSWIRE / April 27, 2022 / Amarantus Bioscience Hol...
Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and instituti...
NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos e...